Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LSTA 
Lisata Therapeutics Inc. (LSTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: LSTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.67
1 Year Target Price $20.67
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.15% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.14M USD | Price to earnings Ratio - | 1Y Target Price 20.67 |
Price to earnings Ratio - | 1Y Target Price 20.67 | ||
Volume (30-day avg) 3 | Beta 1.01 | 52 Weeks Range 1.87 - 4.20 | Updated Date 09/17/2025 |
52 Weeks Range 1.87 - 4.20 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6954.29% |
Management Effectiveness
Return on Assets (TTM) -38.76% | Return on Equity (TTM) -64.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1784320 | Price to Sales(TTM) 18.82 |
Enterprise Value -1784320 | Price to Sales(TTM) 18.82 | ||
Enterprise Value to Revenue 0.32 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 8755950 | Shares Floating 7259644 |
Shares Outstanding 8755950 | Shares Floating 7259644 | ||
Percent Insiders 19.82 | Percent Institutions 8.94 |
Upturn AI SWOT
Lisata Therapeutics Inc.
Company Overview
History and Background
Lisata Therapeutics, Inc. (formerly D u09b8u09c1u09afu09cbu0997, Inc.) focuses on the development of therapies that target the tumor microenvironment. Founded with the goal of enhancing cancer treatments, it has evolved through various stages of clinical development and strategic partnerships.
Core Business Areas
- Drug Development: Developing and commercializing innovative therapies that are designed to modulate the tumor microenvironment and promote efficient and selective delivery of cancer therapeutics to solid tumors.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its lead product candidates in various cancer types.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and biotechnology industries. The organizational structure is designed to support research, clinical development, and potential commercialization efforts.
Top Products and Market Share
Key Offerings
- LSTA (formerly TLX101): Lisata's lead product candidate, designed to target the tumor microenvironment. It's currently in clinical trials for various cancers. Market share is currently 0% as it is still in development phase. Competitors include companies developing similar tumor-targeted therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically oncology, is characterized by high growth potential, intense competition, and significant regulatory hurdles. Tumor microenvironment-targeted therapies represent a growing area of research and development.
Positioning
Lisata is positioned as a company focused on developing innovative therapies that address the challenges of drug delivery in solid tumors. Its competitive advantage lies in its targeted approach to modulating the tumor microenvironment.
Total Addressable Market (TAM)
The global oncology market is vast, expected to reach hundreds of billions of dollars. Lisata's TAM depends on the success of LSTA and its applicability to various cancer types. TAM estimates will be in the hundreds of billions by 2030. Their current position is minimal (less than .0001%)
Upturn SWOT Analysis
Strengths
- Novel targeted therapy approach
- Experienced management team
- Clinical-stage product candidate
- Proprietary technology platform
Weaknesses
- Limited financial resources
- Reliance on a single lead product candidate
- High regulatory risk
- No current revenue generation
Opportunities
- Potential for strategic partnerships
- Expansion into new cancer indications
- Positive clinical trial results
- Advancements in drug delivery technologies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory delays
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- BMRN
- MRTX
- LLY
Competitive Landscape
Lisata's advantage lies in its targeted approach. Disadvantages include limited resources and a reliance on a single product candidate compared to larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth: Limited historical growth due to being in a developmental phase.
Future Projections: Future Projections: Dependent on the success of clinical trials and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent Initiatives: Focus on advancing clinical trials and securing partnerships.
Summary
Lisata Therapeutics is a development-stage biopharmaceutical company focused on tumor microenvironment modulation. It has a promising lead product candidate but faces significant risks related to clinical trials and regulatory approvals. The company's success hinges on the positive outcome of its clinical programs and its ability to secure funding and partnerships. Its lack of revenue and dependence on a single asset make it a speculative investment. Any failure in clinical trials will have a severe negative consequence for the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lisata Therapeutics Inc.
Exchange NASDAQ | Headquaters Basking Ridge, NJ, United States | ||
IPO Launch date 1999-03-01 | President, CEO & Director Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.lisata.com |
Full time employees 26 | Website https://www.lisata.com | ||
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.